Drug Recall: NORepinephrine Injectable Solution Due to Sterility Concerns
Central Admixture Pharmacy Services is recalling NORepinephrine injectable solution nationwide after an FDA inspection questioned the product's sterility assurance. The recall affects 4,994 bags.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard—lack of sterility assurance in a medication product—represents a risk-of-harm where injury has not yet been reported, fitting the 'High' severity criterion.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling NORepinephrine added to 0.9% sodium chloride (4 mg/250 mL, 16 mcg/mL, 250 mL per bag, Rx only). The recall is due to lack of assurance of sterility: an FDA inspection called into question the sterility of products intended to be sterile.
The affected product was distributed nationwide in the United States. The recall affects 4,994 bags, identified by 14 lot numbers with expiration dates ranging from May 2023 through July 2023.
Healthcare facilities and patients who have received this product should not use it. Consult with your healthcare provider regarding this recall.
The recalled product
- Product
- NORepinephrine added to 0.9% sodium chloride, 4 mg/250 mL* (16 mcg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-8097-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable medication
- Hazard
- sterility-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-884510
- Exp 05/04/2023
- 37-885671
- Exp 05/09/2023
- 37-886285
- Exp 05/11/2023
- 37-888322
- Exp 05/21/2023
- 37-888851
- Exp 05/22/2023
- 37-889840
- Exp 05/25/2023
- 37-890130
- Exp 05/28/2023
- 37-890966
- Exp 05/30/2023
- 37-893529
- Exp 06/11/2023
- 37-894766
- Exp 06/14/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27